Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP9X | Q93008 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14716940 | 1.00 | USP9X (0.33) | USP9XKDM4ENPC1RAB9AGAA | |
| SCHEMBL12444819 | 0.87 | KDM4E (0.33) | KDM4ENPC1RAB9AGAAMAPT | |
| SCHEMBL12444814 | 0.84 | TSHR (0.36) | KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL12444816 | 0.73 | DRD2 (0.36) | KDM4EGAAMAPTMAPK1HTT | |
| SCHEMBL12444462 | 0.68 | ACVR1 (0.33) | — | |
| SCHEMBL2326219 | 0.67 | MAPT (0.39) | KDM4EGAAMAPTMAPK1HTT | |
| SCHEMBL2327870 | 0.67 | HPGD (0.43) | KDM4EGAAMAPTMAPK1HTT | |
| SCHEMBL10514464 | 0.67 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL3620002 | 0.66 | KDM4E (0.46) | KDM4EGAAMAPTMAPK1HTT | |
| SCHEMBL12445165 | 0.66 | MAPT (0.37) | KDM4ENPC1RAB9AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED | 2013-02-28 | — | — | US | disclosed |
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED | 2013-02-28 | — | — | US | disclosed |
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED | 2013-02-28 | — | — | US | disclosed |
| WO-2011098776-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | HTR1B, HTR5A, HTR1A | USP9X 2593/4885KDM4E 2422/4885NPC1 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.